Escalating antihypertensives is a sign the pre-eclampsia is winning

Design

retrospective single-centre cohort, 2016 to 2025, multivariable Poisson and linear regression

Population

396 singleton pregnancies managed expectantly for pre-eclampsia with severe features at 23+0 to 33+5 weeks

Primary outcome

composite maternal adverse outcome by number of oral antihypertensive dose escalations

Effect

4.2 percentage points absolute per escalation (95% CI 2.0 to 6.5); aRR 5.20 (1.81 to 14.90) for four or more versus none

A single level IV referral centre looked back at 396 singleton pregnancies managed expectantly for pre-eclampsia with severe features between 23 weeks 0 days and 33 weeks 5 days, over ten years. The exposure was simple and already in every chart: how many times the oral antihypertensive dose was pushed up. About 40 per cent needed no escalation at all; a quarter needed one, a fifth two, and 14 per cent three or more.

Composite maternal harm — abruption, intrauterine death, acute kidney injury, pulmonary oedema, HELLP, eclampsia, stroke, death and others — rose steadily across those bands. Each extra escalation carried an absolute 4.2 percentage point increase in risk (95% CI 2.0 to 6.5). Against no escalation, three escalations gave an adjusted relative risk of 4.07 (1.41 to 11.78) and four or more 5.20 (1.81 to 14.90); escalating daily gave 7.92 (2.90 to 21.63). Repeated intravenous pushes showed the same pattern. Neonatal outcomes were flat across the categories.

The reading is not that antihypertensives harm. It is that the trajectory of treatment is a bedside marker of where the disease is going, available in real time and at no cost. A woman whose pressures are being chased upward every day is not the same woman as one stable on a fixed dose, even if today's numbers look alike. That belongs in the daily decision about whether expectant management continues, and in what is said to her about it.

• Record dose escalations explicitly on the expectant-management chart, not just the current dose
• Count intravenous pushes for severe hypertension separately — they carried the same signal
• Treat an escalation every day or two as a reason to revisit the delivery decision, not only the drug
• Say this out loud in counselling: rising treatment need is information about the illness
• Do not reassure from stable neonatal indices — the risk that moved here was maternal

Why it matters

A number already in every chart turns out to carry prognostic weight nobody is reading.

Don't overread it

This is observational — it does not show that escalating treatment causes harm, or that holding back would help.

The statistics, in plain English

The confidence intervals here are wide — 1.41 to 11.78 for three escalations — because few women reached the higher bands. The direction is consistent and the lower bound stays above 1, so the association is real; the size of it is not pinned down. This is also a retrospective cohort at one centre, so escalation and risk share a common cause (worsening disease) rather than escalation causing the harm.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.